1 – 19 of 19
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Deciphering the genetics and mechanisms of predisposition to multiple myeloma
(
- Contribution to journal › Article
- 2020
-
Mark
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
(
- Contribution to journal › Article
-
Mark
Search for multiple myeloma risk factors using Mendelian randomization
(
- Contribution to journal › Article
-
Mark
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study
(
- Contribution to journal › Article
- 2019
-
Mark
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
(
- Contribution to journal › Article
- 2018
-
Mark
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
(
- Contribution to journal › Article
- 2016
-
Mark
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
(
- Contribution to journal › Article
- 2014
-
Mark
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
(
- Contribution to journal › Article
- 2013
-
Mark
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
(
- Contribution to journal › Article
- 2012
-
Mark
MyelomA Genetics International Consortium
(
- Contribution to journal › Scientific review
-
Mark
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
(
- Contribution to journal › Article
- 2011
-
Mark
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
(
- Contribution to journal › Article
- 2010
-
Mark
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma.
(
- Contribution to journal › Article
- 2009
-
Mark
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
(
- Contribution to journal › Article
- 2005
-
Mark
International Staging System for Multiple Myeloma.
(
- Contribution to journal › Article